CYX Calyx Ventures Inc

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR
DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.


Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) ("Calyx" or the "Company") announce a
proposed non-brokered private placement of up to 35,000,000 units at a price of
$0.06 per unit (each a "Unit") for cash proceeds of up to $2,100,000 (the
"Private Placement"). Each Unit comprises one common share and one common share
purchase warrant (each a "Warrant"). Each Warrant will entitle the holder to
acquire one additional common share of the Company at a price of $0.09 for a
period of twenty four months from the closing of the Private Placement, subject
to certain acceleration provisions in the event that the shares of the company
trade at 15 cents or higher for 10 consecutive trading days. The Company expects
that it will pay an 8% cash finders' fee and finders' warrants equal to 8% of
the Units placed, and having the same terms as the Warrants, on all or a portion
of the Private Placement. 


The funds raised from the issuance of the Units will be for general working
capital and potential further investment into Agrisoma or other businesses in
the tech, agriculture and biotech sectors including the MMPR (Marijuana for
Medical Purposes Regulations) and the agri-pharmaceutical space.


Further to the updates issued on March 24 and 26, 2014, Calyx continues to
consider financing solutions for Agrisoma that work for all of Agrisoma's
stakeholders. 


About Calyx 

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
currently focused on renewable fuels including biojet and biodiesel. Calyx is a
shareholder of Agrisoma Biosciences Inc., a company which is producing a new
proprietary non-food energy feedstock crop - carinata - which yields oil that
can be refined into fuels that work in existing engines as a 100 percent
petroleum substitute. From seed to sky, fuels produced from carinata
substantially reduce carbon and other harmful emissions, and help to reduce
global petroleum dependence. Carinata was used to fly the world's first 100%
biojet flight, as achievement that Popular Science called one of the top science
events on the planet in 2012. For further information about Calyx, please visit
www.calyxbio.com. For more information on Agrisoma, please visit
www.agrisoma.com. 


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control, including the completion of the
Private Placement and the delay or failure to receive regulatory approvals., 


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect. In addition to other assumptions
identified in this news release, assumptions have been made regarding, among
other things, timing and completion of the Private Placement, the actual use of
proceeds, and the timing of receipt of regulatory approvals. 


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604-649-5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From May 2024 to Jun 2024

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From Jun 2023 to Jun 2024